Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mismatch-repair deficient (MSI-high) colorectal cancer, drawn from the whole corpus: 90 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
A third of metastatic patients progress early on immunotherapy and the resistance mechanisms are only partly understood.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Whether surgery can be omitted after complete response in colon, as in rectal, cancer is untested.
WRN helicase inhibitors, a synthetic-lethal approach, are in early trials.
Lynch carriers still get cancers between colonoscopies; a preventive vaccine is in randomised testing.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 21 changes by month →When this page itself was last checked or edited.
Primary endpoint (sustained cCR at 12 months) met; rates pending congress presentation.
With nivolumab first-line MSI-H/dMMR colorectal cancer (CheckMate 8HW)
Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with nivolumab
Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab
Unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab